Ficerafusp alfa
GORTEC 2025-01
Phase 2 small_molecule active
Quick answer
Ficerafusp alfa for Squamous Cell Carcinoma of Head and Neck (SCCHN) is a Phase 2 program (small_molecule) at Bicara Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bicara Therapeutics
- Indication
- Squamous Cell Carcinoma of Head and Neck (SCCHN)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active